Director of Research
Beth Israel Deaconess Cancer Center
Harvard Medical School, Boston, MA
Motivation:
Dr. Pier Paolo Pandolfi is honored for his work in the field of cancer genetics and mouse models for cancer. His groundbreaking work is outstanding and has contributed to new therapies for treating cancer.
The research carried out in Dr. Pandolfi’s laboratory has been important in understanding the molecular mechanisms and genetics underlying the pathogenesis of leukemias, lymphomas and solid tumors, as well as in modeling these cancers in mice.
Among his many accomplishments, Dr. Pandolfi and colleagues have characterized the function of oncoproteins and genes involved in the chromosomal translocations of APL in addition to major tumor suppressors such as PTEN and p53, and novel proto-oncogenes, such as POKEMON. These accomplishments have led to the development of novel and effective therapeutic strategies, and, as a result, APL is now considered a curable disease.
Additional novel therapeutic concepts have emerged from Dr. Pandolfi’s research, which are currently being tested in clinical trials. More recently, Pandolfi and colleagues have presented a new theory describing how mRNA, both coding and non-coding, exerts biological functions with profound implications for human genetics, cell biology and cancer biology.
In 1994, Dr. Pandolfi became an assistant member of the molecular biology program and the department of human genetics at Memorial Sloan-Kettering Cancer Center. He grew through the ranks to become a member in the cancer biology and genetics program at the Sloan-Kettering Institute; professor of molecular biology and human genetics, and professor of molecular biology in pathology and laboratory medicine at the Weill Graduate School of Medical Sciences at Cornell University; and head of the molecular and developmental biology laboratories, and the incumbent of the Albert C. Foster Endowed Chair for Cancer Research at Memorial Sloan-Kettering Cancer Center.
Among his lauded career experiences, Dr. Pandolfi has also received numerous awards including: the LLSA Scholar Award (1997); the Irma T. Hirschl Trust Award (1999); the Alexandra J. Kefalides Prize for Leukemia Research (1999); the Hamdan Award for Medical Research Excellence (2000); the Lombroso Prize for Cancer Research of the Weizmann Institute of Science (2001); the Leukemia and Lymphoma Society’s Stohlman Scholar Award (2002); the William and Linda Steere Foundation Award (2004); and, the prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation (2005).
He also has been awarded the National Institutes of Health MERIT Award, the Fondazione Cortese International Award, the Prostate Cancer Foundation Creativity Award and the Ischia International Award. In 2006, Pandolfi was elected as a member of the American Society for Clinical Investigation and the American Association of Physicians, and the following year he became a member of the European Molecular Biology Organization.
Dr. Pandolfi received his medical degree in 1989 and his doctorate in 1995 from the University of Perugia in Italy, after he studied philosophy at the University of Rome. He received post-graduate training at the National Institute for Medical Research and the University of London in the United Kingdom.
Dr. Pandolfi is the George C. Reisman Professor of Medicine and a professor of pathology at Harvard Medical School; director of research at the Beth Israel Deaconess Cancer Center; and director of the cancer genetics program and chief of the division of genetics in the department of medicine at the Beth Israel Deaconess Medical Center. His studies have had an impact on the cancer research arena by broadening the understanding of the molecular basis of cancer.
